Laura Steele succeeds Ashley Diaz-Granados in top Northern Europe role at Lilly

11 August 2021

US pharma major Eli Lilly (NYSE: LLY) has named Laura Steele president and general manager for UK, Ireland and Northern Europe.

She succeeds Ashley Diaz-Granados, who assumes a senior role within Lilly USA, leading the company’s Immunology division.

Ms Steele will lead Lilly’s commercial business operations in six countries, across the company’s current and emerging portfolio in Diabetes, Oncology, Immunology and Neuroscience. The group is currently on a drive to launch at least 20 medicines in the 10 years from 2014 to 2023.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK